ChordNews
← All news

Novo Nordisk raises full-year outlook as Wegovy pill sales beat estimates

By ChordNews · First written (new coverage , updated )

Beleaguered Novo offers relief to investors, thanks to Wegovy pill
Image: marketwatch.com
Comments 0

Summary

Novo Nordisk posted quarterly earnings ahead of expectations early Wednesday, as sales of its Wegovy pill beat estimates, and raised its full-year outlook. CNBC reports that the company's shares jumped 6% on the news. MarketWatch reports that the stock rose Wednesday after the Danish drugmaker lifted its guidance on strong uptake of the weight-loss pill, which launched this year. Seeking Alpha reports that Novo improved its outlook on continued demand for the Wegovy pill and Ozempic.

This continues an earlier story: Eli Lilly raises revenue outlook on weight-loss drug demand

Timeline

  1. Seeking Alpha

    Source ↗

    Seeking Alpha reports that Novo improved its outlook on continued demand for its Wegovy pill and Ozempic.

  2. MarketWatch

    Source ↗

    MarketWatch reports that Novo Nordisk stock jumped on Wednesday as the Danish drugmaker lifted its guidance on strong uptake of its weight-loss pill, launched this year.

  3. CNBC

    Source ↗

    CNBC reports that Novo posted quarterly earnings ahead of expectations early Wednesday, with sales of its Wegovy pill blowing past estimates, and that the company raised its full-year outlook, with shares up 6%.

Comments

No comments yet.

    to like and comment.

    © 2026 ChordNews